Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.51 |
| ▸ | LMNA | P02545 | 3/20 | 0.51 |
| ▸ | GAA | P10253 | 2/20 | 0.51 |
| ▸ | HPGD | P15428 | 1/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.50 |
| ▸ | HTT | P42858 | 2/20 | 0.49 |
| ▸ | POLB | P06746 | 2/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16855653 | 0.88 | MAPT (0.45) | MAPTALDH1A1SMN1; SMN2LMNAGAA | |
| SCHEMBL28100567 | 0.85 | SLC2A1 (0.47) | MAPTALDH1A1SMN1; SMN2LMNAGAA | |
| SCHEMBL16832771 | 0.85 | MAPT (0.63) | MAPTALDH1A1SMN1; SMN2LMNAGAA | |
| SCHEMBL16832373 | 0.84 | ALDH1A1 (0.58) | MAPTALDH1A1SMN1; SMN2LMNAGAA | |
| SCHEMBL16832686 | 0.81 | LMNA (0.63) | ALDH1A1SMN1; SMN2LMNAGAAHPGD | |
| SCHEMBL16832720 | 0.81 | ALDH1A1 (0.66) | ALDH1A1SMN1; SMN2LMNAGAACYP3A4 | |
| SCHEMBL16832460 | 0.80 | GFER (0.63) | ALDH1A1SMN1; SMN2LMNAGAAHPGD | |
| SCHEMBL16832713 | 0.79 | LMNA (0.60) | MAPTALDH1A1SMN1; SMN2LMNAGAA | |
| SCHEMBL16832266 | 0.79 | LMNA (0.52) | MAPTALDH1A1SMN1; SMN2LMNAGAA | |
| SCHEMBL16832399 | 0.79 | KDM4E (0.62) | ALDH1A1GAAPOLBKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170037028-A1 | GLUCOSE TRANSPORT INHIBITORS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-02-09 | — | — | US | disclosed |
| US-20170037028-A1 | GLUCOSE TRANSPORT INHIBITORS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-02-09 | — | — | US | disclosed |
| EP-3083598-A1 | GLUCOSE TRANSPORT INHIBITORS | Bayer Pharma Aktiengesellschaft (DE) | 2016-10-26 | — | — | EP | disclosed |
| CN-106029647-A | Glucose transport inhibitors | 拜耳制药股份公司 | 2016-10-12 | — | — | CN | disclosed |
| WO-2015091428-A1 | GLUCOSE TRANSPORT INHIBITORS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2015-06-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170037028-A1 | GLUCOSE TRANSPORT INHIBITORS | SLC2A1, SLC2A2, SLC2A4 | MAPT 526/4885ALDH1A1 432/4885SMN1; SMN2 1640/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.